CANDEL THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Fair Value
CANDEL THERAPEUTICS, INC. (CADL) reported Adjustments to Additional Paid in Capital, Fair Value of $848.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. adjustments to additional paid in capital, fair value for the quarter ending 2026-06-30 was $848.00K.
- CANDEL THERAPEUTICS, INC. adjustments to additional paid in capital, fair value for the quarter ending 2026-03-31 was -$127.00K.
- CANDEL THERAPEUTICS, INC. adjustments to additional paid in capital, fair value for the quarter ending 2025-12-31 was $83.00K, a 70.98% decline year-over-year.
- CANDEL THERAPEUTICS, INC. adjustments to additional paid in capital, fair value for the quarter ending 2025-09-30 was $2.00K, a 98.18% decline year-over-year.
- CANDEL THERAPEUTICS, INC. adjustments to additional paid in capital, fair value for fiscal 2025 was -$498.00K, a 143.61% decline from fiscal 2024.
- CANDEL THERAPEUTICS, INC. adjustments to additional paid in capital, fair value for fiscal 2024 was $1.14M.
- CANDEL THERAPEUTICS, INC. adjustments to additional paid in capital, fair value for fiscal 2023 was -$46.00K.
- CANDEL THERAPEUTICS, INC. adjustments to additional paid in capital, fair value for fiscal 2022 was -$838.00K, a 323.47% decline from fiscal 2021.
| Period end | Adjustments to Additional Paid in Capital, Fair Value 3 month | Adjustments to Additional Paid in Capital, Fair Value 6 month | Adjustments to Additional Paid in Capital, Fair Value 9 month | Adjustments to Additional Paid in Capital, Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $848.00K 10-Q · filed 2026-08-13 | $721.00K 10-Q · filed 2026-08-13 | $804.00K derived: sum of 3 quarters · filed 2026-08-13 | $806.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$127.00K 10-Q · filed 2026-05-14 | -$44.00K derived: sum of 2 quarters · filed 2026-05-14 | -$42.00K derived: sum of 3 quarters · filed 2026-05-14 | -$141.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $85.00K derived: sum of 2 quarters · filed 2026-03-12 | -$14.00K derived: sum of 3 quarters · filed 2026-08-13 | -$498.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.00K 10-Q · filed 2025-11-13 | -$97.00K derived: sum of 2 quarters · filed 2026-08-13 | -$581.00K 10-Q · filed 2025-11-13 | -$295.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$99.00K 10-Q · filed 2026-08-13 | -$583.00K 10-Q · filed 2026-08-13 | -$297.00K derived: sum of 3 quarters · filed 2026-08-13 | -$187.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$484.00K 10-Q · filed 2026-05-14 | -$198.00K derived: sum of 2 quarters · filed 2026-05-14 | -$88.00K derived: sum of 3 quarters · filed 2026-05-14 | $645.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $286.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $396.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.13M derived: sum of 3 quarters · filed 2026-03-12 | $1.14M 10-K · filed 2026-03-12 |
| 2024-09-30 | $110.00K 10-Q · filed 2025-11-13 | $843.00K derived: sum of 2 quarters · filed 2025-11-13 | $856.00K 10-Q · filed 2025-11-13 | $936.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $733.00K 10-Q · filed 2025-08-14 | $746.00K 10-Q · filed 2025-08-14 | $826.00K derived: sum of 3 quarters · filed 2025-08-14 | $777.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $13.00K 10-Q · filed 2025-05-13 | $93.00K derived: sum of 2 quarters · filed 2025-05-13 | $44.00K derived: sum of 3 quarters · filed 2025-05-13 | $31.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $31.00K derived: sum of 2 quarters · filed 2025-03-13 | $18.00K derived: sum of 3 quarters · filed 2025-03-13 | -$46.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$49.00K 10-Q · filed 2024-11-14 | -$62.00K derived: sum of 2 quarters · filed 2024-11-14 | -$126.00K 10-Q · filed 2024-11-14 | -$329.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$13.00K 10-Q · filed 2024-08-13 | -$78.00K 10-Q · filed 2024-08-13 | -$280.00K derived: sum of 3 quarters · filed 2024-08-13 | -$294.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$65.00K 10-Q · filed 2024-05-14 | -$267.00K derived: sum of 2 quarters · filed 2024-05-14 | -$281.00K derived: sum of 3 quarters · filed 2024-05-14 | -$568.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$216.00K derived: sum of 2 quarters · filed 2024-03-28 | -$503.00K derived: sum of 3 quarters · filed 2024-03-28 | -$838.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | -$14.00K 10-Q · filed 2023-11-09 | -$301.00K derived: sum of 2 quarters · filed 2023-11-09 | -$636.00K 10-Q · filed 2023-11-09 | -$1.11M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$287.00K 10-Q · filed 2023-08-10 | -$622.00K 10-Q · filed 2023-08-10 | -$1.09M derived: sum of 3 quarters · filed 2023-08-10 | -$497.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$335.00K 10-Q · filed 2023-05-11 | -$805.00K derived: sum of 2 quarters · filed 2023-05-11 | -$210.00K derived: sum of 3 quarters · filed 2023-05-11 | $40.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$470.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $125.00K derived: sum of 2 quarters · filed 2023-03-30 | $375.00K derived: sum of 3 quarters · filed 2023-03-30 | $375.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $595.00K 10-Q · filed 2022-11-10 | $845.00K derived: sum of 2 quarters · filed 2022-11-10 | $845.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $250.00K 10-Q · filed 2022-08-05 | $250.00K 10-Q · filed 2022-08-05 | ||
| 2020-12-31 | $475.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $475.00K derived: sum of 2 quarters · filed 2022-03-29 | $695.00K derived: sum of 3 quarters · filed 2022-03-29 | $695.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $220.00K derived: sum of 2 quarters · filed 2021-11-12 | $220.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $220.00K 10-Q · filed 2021-09-08 | $220.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |